People · Operator
Named in public records as an officer, director or promoter · active 2009–2023 · Pharmaceuticals, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Talphera, Inc. | — | Pharmaceuticals | Series B | $97.4M | $74.2M | 2022 |
| Pearl Therapeutics Inc | — | Pharmaceuticals | Series B | $74.0M | $791.4M | 2010 |
| ALDEA Pharmaceuticals, Inc. | — | Biotechnology | Series A | $27.5M | $334.9M | 2011 |
| Hopewell Therapeutics, Inc. | — | Biotechnology | Series A | $25.9M | $7.5M | 2023 |
| Cns Therapeutics Inc | — | Pharmaceuticals | Series A | $13.1M | $94.5M | 2009 |
Howard Rosen at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Howard Rosen on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Howard B. Rosen | 2 | 4 |
| John Walker | 1 | 17 |
| Wende Hutton | 1 | 16 |
| Nina Kjellson | 1 | 11 |
| John Foster | 1 | 10 |
| Mark Wan | 1 | 10 |
| Timothy Shannon | 1 | 9 |
| Stephen Hoffman | 1 | 7 |
| Peter McNerney | 1 | 6 |
| Guy Nohra | 1 | 5 |
| Pratik Shah | 1 | 5 |
| Mark Edwards | 1 | 4 |
| James Welch | 1 | 4 |
| James Young | 1 | 4 |
| Marina Bozilenko | 1 | 3 |
| JAMES W. YOUNG | 1 | 3 |
| Richard King | 1 | 3 |
| James H. Welch | 1 | 3 |
| Thomas Hennessey | 1 | 3 |
| William Yelle | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.